TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Plus Therapeutics ( (PSTV) ) has shared an update.
On August 22, 2025, Plus Therapeutics, Inc. received confirmation from Nasdaq that it complies with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities standard and the alternative stockholders’ equity threshold. This compliance allows the company to extend its grace period to meet the $1.00 bid price rule until November 12, 2025. However, the company is subject to a one-year monitoring period regarding the Equity Standard. If it fails to maintain compliance within this period, Nasdaq will issue a delist determination letter, though the company can request a hearing to potentially stay further actions.
The most recent analyst rating on (PSTV) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Plus Therapeutics stock, see the PSTV Stock Forecast page.
Spark’s Take on PSTV Stock
According to Spark, TipRanks’ AI Analyst, PSTV is a Neutral.
The overall score reflects significant financial challenges and valuation concerns, partially offset by strategic corporate actions to improve compliance and financial flexibility. Technical indicators are mixed, suggesting cautious optimism.
To see Spark’s full report on PSTV stock, click here.
More about Plus Therapeutics
Average Trading Volume: 31,537,431
Technical Sentiment Signal: Sell
Current Market Cap: $48.15M
For a thorough assessment of PSTV stock, go to TipRanks’ Stock Analysis page.